News

Cognes Granted U.S. Patent for AI-Powered Early Dementia Detection Platform

Stockholm, Sweden – June 2024 – Cognes Medical Solutions has been granted a U.S. patent for its AI-powered dementia detection platform, marking a significant step toward revolutionizing early diagnosis and care for neurodegenerative diseases. The patented solution analyzes facial features using machine learning to identify early signs of cognitive decline. Delivered via a smartphone app, […]

Cognes Granted U.S. Patent for AI-Powered Early Dementia Detection Platform Read More »

Cognes Recognized at Brilliant Minds 2025 for Breakthrough in Early Dementia Detection

Leading the Future of AI-Powered Dementia Detection Cognes wins Brilliant Minds 2025 for its AI-driven dementia screening tool using facial biomarkers. A milestone for innovation in healthtech and longevity. A Global Spotlight on AI and Early Dementia Detection Cognes Medical Solutions, an emerging force in AI-powered healthtech, has been named the Brilliant Minds Innovator of

Cognes Recognized at Brilliant Minds 2025 for Breakthrough in Early Dementia Detection Read More »

Cognes Medical Solutions Selected Among Top 100 Innovators Advancing to the Entrepreneurship World Cup Global Finals

Cognes Medical Solutions Selected Among Top 100 Innovators Advancing to the Entrepreneurship World Cup Global Finals Cognes Medical Solutions is thrilled to announce its selection as one of the Top 100 companies advancing to the prestigious Entrepreneurship World Cup (EWC) Global Finals. Cognes will join an elite group of startups from 52 countries competing for

Cognes Medical Solutions Selected Among Top 100 Innovators Advancing to the Entrepreneurship World Cup Global Finals Read More »

Unraveling Alzheimer’s: Confronting the Effect on Mortality

Today, Alzheimer’s is one of the most prevalent diseases in America, affecting about 11.3% of all people aged 65 years and over. In 2021, there were about 6.2 million people with Alzheimer’s, with the number expected to more than double and reach 13 million by 2050 should a cure not be found. It typically affects the seniors, with 72% of the 6.2 million people living with Alzheimer’s being over 75 years old.

Unraveling Alzheimer’s: Confronting the Effect on Mortality Read More »

Physician at work

Why Are Alzheimer’s Disease Clinical Trials So Challenging To Carry Out?

Alzheimer’s disease is one of the most difficult diseases to understand and develop new treatments for. Clinical trials for Alzheimer’s are expensive and lengthy and even when funding exists, it can be hard to find participants for them in time to optimize testing results. Also, because they have a traditionally high failure rate, they generate reticence, hesitation, and bias.

Why Are Alzheimer’s Disease Clinical Trials So Challenging To Carry Out? Read More »

Scroll to Top